登录 注册 会员服务 联系我们

Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study

  • Published:2017-09-23 Issue:12 Volume:56 Page:2170-2178
  • ISSN:1462-0324
  • Container-title:Rheumatology
  • language:en
  • Short-container-title:

Author:

Tausche Anne-Kathrin,Alten Rieke,Dalbeth Nicola,Kopicko Jeff,Fung Maple,Adler Scott,Bhakta Nihar,Storgard Chris,Baumgartner Scott,Saag Kenneth

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Reference19 articles.

1. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia;Arthritis Care Res,2012

2. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol;Pharmacol Rev,2006

3. 2016 updated EULAR evidence-based recommendations for the management of gout;Ann Rheum Dis,2016

4. RDEA594: a potent URAT1 inhibitor without affecting other important renal transporters, OAT1 and OAT3 [abstract];Ann Rheum Dis,2009

5. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia;Rheumatology,2014
同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3